PROMETHEUS BIOSCIENCES INC (RXDX) Stock Price, Forecast & Analysis
USA - NASDAQ:RXDX - US74349U1088 - Common Stock
RXDX Key Statistics, Chart & Performance
The current stock price of RXDX is 199.92 USD. In the past month the price increased by 3.62%. In the past year, price increased by 684.31%.
RXDX Latest News, Press Relases and Analysis
RXDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About RXDX
Company Profile
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
Company Info
PROMETHEUS BIOSCIENCES INC
3050 Science Park Road, #342
San Diego CALIFORNIA 92121 US
CEO: Mark C. McKenna
Employees: 97
Phone: 18584224300.0
PROMETHEUS BIOSCIENCES INC / RXDX FAQ
Can you describe the business of PROMETHEUS BIOSCIENCES INC?
Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 97 full-time employees. The company went IPO on 2021-03-11. The firm discovers, develops and commercializes therapeutic products for the treatment of immune-mediated diseases, inflammatory bowel disease. Its precision medicine platform, Prometheus360, includes gastrointestinal bioinformatics databases and sample biobanks, to identify therapeutic targets, develop therapeutic candidates to engage those targets, and develop genetics-based diagnostic tests designed to identify patients to respond to its therapeutic candidates. Its lead product candidate, PRA023, is a humanized IgG1 monoclonal antibody (mAb) that has been shown to block the tumor necrosis factor (TNF). Its second product candidate, PRA052, is an anti-CD30L mAb. The CD30L-CD30 co-stimulatory pathway has been implicated in IBD by genetic, preclinical and human translational data. Its PR1100 program targets the receptor for a pro-inflammatory cytokine that has been linked to multiple immune-mediated diseases.
What is the stock price of PROMETHEUS BIOSCIENCES INC today?
The current stock price of RXDX is 199.92 USD. The price increased by 0.09% in the last trading session.
What is the dividend status of PROMETHEUS BIOSCIENCES INC?
RXDX does not pay a dividend.
What is the ChartMill rating of PROMETHEUS BIOSCIENCES INC stock?
RXDX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists RXDX stock?
RXDX stock is listed on the Nasdaq exchange.
How many employees does PROMETHEUS BIOSCIENCES INC have?
PROMETHEUS BIOSCIENCES INC (RXDX) currently has 97 employees.
RXDX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RXDX. When comparing the yearly performance of all stocks, RXDX is one of the better performing stocks in the market, outperforming 99.86% of all stocks.
RXDX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RXDX. RXDX has a great financial health rating, but its profitability evaluates not so good.
RXDX Financial Highlights
Over the last trailing twelve months RXDX reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS decreased by -26.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RXDX Forecast & Estimates
15 analysts have analysed RXDX and the average price target is 198.9 USD. This implies a price decrease of -0.51% is expected in the next year compared to the current price of 199.92.
For the next year, analysts expect an EPS growth of -16.9% and a revenue growth -69.44% for RXDX